MICHAEL A PULSIPHER portrait
  • Professor, Pediatrics
801-588-2680

Presentations

  • Pulsipher MA. Overview of Hematopoietic Transplant Transplantation: Delivering the Best Therapy to High Risk Cancer Patients. High Dose Therapy and Stem Cell Transplantation: New Horizons, Mountain States Tumor Institute, Boise, ID. , , 2006.
  • Pulsipher MA (Symposium Chair & Speaker). New Transplant, Cellular, and Immunological Approaches to CR3 ALL. Children’s Oncology Group Meeting, Dallas, TX. , , 2005.
  • Pulsipher MA. The Role of Transplantation in Pediatric ALL. Mountain States Tumor Institute, Boise, ID. , , 2005.
  • Pulsipher MA. Hematopoietic Cell Transplantation in Patients with MPS-I: Patient Risk Factors and New Approaches. Training Program on Lysosomal Storage Diseases, Salt Lake City, UT. , , 2005.
  • Pulsipher MA. Treatment of Pediatric ALL in Developing Countries. St. Mary's Mission Hospital, Langata, Kenya. , , 2005.
  • Pulsipher MA. G-CSF Use in Normal Pediatric Donors: Risks, Benefits, and Ethical Considerations. Scientific Seminar, Children’s Oncology Group Meeting, Atlanta, GA. , , 2004.
  • Pulsipher MA. The Role of Hematopoietic Cell Transplantation to Treat Patients with MPS-I. Training Program on Lysosomal Storage Diseases, Salt Lake City, UT. , , 2004.
  • Pulsipher MA. Late Effects after Hematopoietic Stem Cell Transplantation. High Dose Therapy and Stem Cell Transplantation: New Horizons, Mountain States Tumor Institute, Boise, ID. , , 2004.
  • Pulsipher MA. Safety and Efficacy of PBSC Collection in Normal Pediatric Donors: Implications for Donor Safety and Monitoring in the Pediatric Population. Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues, National Heart, Lung, and Blood Institute, Arlington, VA. , , 2004.
  • Pulsipher MA. Overview of Pediatric Transplantation. High Dose Therapy and Stem Cell Transplantation: New Horizons, Mountain States Tumor Institute, Boise, ID. , , 2003.
  • Pulsipher MA (Invited Speaker & Moderator). Adoptive Immunotherapy for Treatment of Hematologic and Solid Tumors. Session on Cellular Therapies at Stem Cell Therapies: From Test Tube to Current Clinical Trials, Huntsman Cancer Institute, Salt Lake City, UT. , , 2002.
  • Pulsipher MA. Long-Term Side Effects of Allogeneic Bone Marrow Transplantation. Mountain States Tumor Institute, Boise, ID. , , 2002.
  • Pulsipher MA, Goyal R, Frangoul H, Shaw P, Haight A, Kadota R, Wall D, Grupp S, Kletzel M. Low Rates of Toxicity and Long-Term Responses After BU/FLU/ATG RIC Allogeneic Transplantation in Very High Risk Pediatric Patients Ineligible for Myeloablative Therapy: A Pediatric Blood and Marrow Transplant Consortium. American Society for Blood and Marrow Transplantation Meeting, Keystone, CO. abst #73. , , 2007.
  • Pulsipher MA, Wall D, Goyal R, Bunin N, Grupp S. Sirolimus (SRL)-Based GVHD Prophylaxis to Decrease Relapse in Pediatric Related and Unrelated Transplant Recipients with Very High-Risk ALL: Preliminary Results of a Multi-Institutional Pilot Study. American Society for Blood and Marrow Transplantation Meeting, Keystone, CO. abst #74. , , 2007.
  • Goyal RK, Venkataramanan R, Krasowski M, Sindhi R, Zorich GP, Grupp S, Wall D, Bunin N, Pulsipher MA. Therapeutic Monitoring of Sirolimus is Essential in Pediatric BMT Recipients. American Society for Blood and Marrow Transplantation Meeting, Keystone, CO. abst #69. , , 2007.
  • Pulsipher M, Chitphakdithai P, Klein J, Kurian S, Leitman S, Anderlini P, Logan B, Horowitz MM, and Confer DL. Volunteer Unrelated Donor PBSC Collection Efficacy and Recipient Outcomes: Results of a Prospective National Marrow Donor Program (NMDP) Trial, 1999-2003. American Society of Hematology Meeting, Orlando, FL, abst #169. , , 2006.
  • Pulsipher MA. Hematopoietic Stem Cell Donor Safety: What Do We Know, What Should We Know? American Association of Blood Banks Annual Meeting, Miami, FL. , , 2006.
  • Sorror M, Storer B, Sandmaier BM, Malone DG, Pulsipher M, Langston A, Maris MB, Niederwieser D, Storb R. The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT). American Society of Hematology Annual Meeting, Orlando, FL. abst#596. , , 2006.
  • Pulsipher MA. Donor Safety Studies in the CIBMTR: Current Status, Future Prospects. World Marrow Donor Association, American Society of Hematology Meeting, Atlanta, GA. , , 2005.
  • Sandmaier B, Maris M, Maloney D, Gooley T, Shizuru D, Niederwieser T, Chauncey T, Sahebi F, Agura E, Maziarz R, Bruno B, Pulsipher M, Langston A, Wade J, McSweeney P, Epner E, Bethge W, Forman S, Blume K, Storb R. Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning. American Society of Hematology Annual Meeting, Atlanta, GA. abst#655. , , 2005.
  • Kerbauy F, Maris M, Storer B, Maloney D, Niederwieser D, Agura E, Pulsipher M, Chauncey T, Maziarz R, Forman S, Langston A, Wade J, Scott B, Deeg J, Storb R, Sandmaier B. Efficacy of Nonmyeloablative Hematopoietic Cell Transplant (HCT) in Secondary Myelodysplastic Syndrome (MDS) and Its Impact on the Primary Disease. American Society of Hematology Annual Meeting, Atlanta, GA. abst#792. , , 2005.
  • Burroughs L, Storb R, Leisenring W, Pulsipher M, Loken M, Torgerson T, Ochs H, Woolfrey A. Postgrafting Immune Suppression Combined with Nonmyeloablative Conditioning for Transplantation of HLA-Identical Hematopoietic Cell Grafts: Results of a Phase I Study for Treatment of Immunodeficiency Disorders. American Society of Hematology Annual Meeting, Atlanta, GA. abst#327. , , 2005.
  • Kahl C, Storer B, Mielcarek M, Maris M, Sandmaier B, Maloney D, Chauncey T, Niederwieser D, McSweeney P, Bruno B, Blume K, Wade J, Leis J, Langston E, Pulsipher M, Agura E, Storb R. Relapse Risk after Nonmyeloablative Hematopoietic cell Transplantation for Malignant Diseases. American Society of Hematology Annual Meeting, Atlanta, GA. abst#703. , , 2005.
  • Sandmaier BM, Maloney DG, Maris MB, Chauncey TR, Pulsipher MA, Bethge W, Little MT, Storb R. Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI). American Society of Hematology Annual Meeting, San Diego, CA. abst#186. , , 2004.
  • Baron F, Maris M, Sandmaier B, Storer B, Stuart M, McSweeney P, Radich J, Pulsipher M, Agura E, Petersdorf E, Heimfeld S, Chauncey T, Little MT, Maloney D, Blume K, Storb R. HLA-Matched Unrelated Donor HCT after Nonmeyloablative Conditioning for Patients with Chronic Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego, CA. abst#2755. , , 2004.
  • Pulsipher M, Levine JE, Hayashi R, Chan K, Anderson P, Duerst R, Grupp SA. 388] Safety and Efficacy of Allogeneic PBSC Collection in Normal Pediatric Donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996-2003. American Society of Hematology Annual Meeting, San Diego, CA. , , 2003.
  • Sorror ML, Storer B, Sandmaier BM, Maris MB, Shizuru F, Niederwieser D, Agura E, Chauncey T, Maziarz R, Pulsipher M, McSweeney P, Wade F, Bruno B, Langston A, Blume K, Storb R, Maloney DG. Longer Follow Up of Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL) Treated with Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT). American Society for Blood and Marrow Transplantation Meeting, Keystone, CO. abst#368. Poster, Presented, 2007.
  • Cao TM, Tsai S, Kelley L, Alder SC, Fuller TC, Pulsipher MA. Comparable Survival and Transplant-Related Mortality Following Allogeneic Hematopoietic Cell Transplantation from HLA Allele-Matched Unrelated and HLA-Identical Sibling Donors. American Society of Hematology Meeting, Orlando, FL. abst#3146. Poster, Presented, 2006.
  • Pulsipher M, Wall D, Grupp S, Goyal R, Bunin N. Low Rates of Toxicity, GVHD and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL. American Society of Hematology Annual Meeting, Orlando, FL. abst#2876. Poster, Presented, 2006.
  • Rezvani AR, Sandmaier BM, Storer B, Maris M, Agura E, Maziarz R, Wade JC, Chauncey T, Forman SJ, Niederwieser DW, Shizuru J, Langston A, Pulsipher M, Storb RF, Malone DG. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory or Transformed Indolent Non-Hodgkin Lymphoma (NHL). American Society of Hematology Meeting, Orlando, FL. abst#3124. Poster, Presented, 2006.
  • Witty S, Hayashi R, Barnes Y, Yu L, Dalal J, Kamani N, Pulsipher MA, Shenoy S. Infectious Complications Following Stem Cell Transplant for Non-Malignant Disorders Using a Novel Reduced Intensity Conditioning Approach. American Society for Blood and Marrow Transplantation Meeting, Honolulu, HI. abst#508. Poster, Presented, 2006.
  • Baron F, Sandmaier BM, Storer B, Maris M, Langston A, Niederwieser DW, Petersdorf E, Bethge W, Maziarz RT, McSweeney P, Pulsipher M, Wade JC, Chauncey T, Shizuru J, Woolfrey A, Maloney DG, Storb RF. Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed to Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning. American Society of Hematology Annual Meeting, Orlando, FL. abst#3119. Poster, Presented, 2006.
  • Georges G, Maris M, Maloney D, Sandmaier B, Sorror M, Shizuru J, Niederwieser D, Agura E, Bruno B, McSweeney P, Pulsipher M, Chauncey T, Storer B, Storb R. Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma. American Society for Blood and Marrow Transplantation Meeting, Honolulu, HI. abst#46. Poster, Presented, 2006.
  • Pulsipher M, Kurian S, Leitman S, Anderlini P, Haagenson M, Logan B, Horowitz M, Confer D. Unrelated-Donor PBSC Collection Facilitated by the NMDP, 1999-2005: Efficacy and Toxicities, Serious Unexpected Events, and Outcomes of Standard vs. Large Volume Collections. American Society of Hematology Meeting, Atlanta, GA. abst#1965. Poster, Presented, 2005.
  • Georges G, Maris M, Maloney D, Sandmaier B, Sorror M, Shizuru J, Niederwieser D, Agura E, Bruno B, McSweeney P, Pulsipher M, Chauncey T, Storer B, Storb R. Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma. American Society of Hematology Meeting, Atlanta, GA. abst#2893. Poster, Presented, 2005.
  • Frangoul H, Woolfrey A, Khan S, Pulsipher M, Levine J, Baker D, Walters M, Ayas M, Ravindranath Y, Grupp S, Billheimer D, Nemecek E. A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study. American Society of Hematology Meeting, Atlanta, GA. Poster, Presented, 2005.
  • Baron F, Storb R, Storer B, Maloney D, Maris M, Niederwieser D, Shizuru J, Chauncey T, Bruno B, Forman S, McSweeney P, Maziarz R, Pulsipher M, Agura E, Sorror M, Wade J, Sandmaier B. Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes. American Society of Hematology Meeting, Atlanta, GA. Poster, Presented, 2005.
  • Wendland MM, Smith DC, Boucher KM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK. The Impact of Involved Field Radiation Therapy for Patients Receiving High Dose Chemotherapy Followed by Hematopoietic Progenitor Cell Transplant for the Treatment of Relapsed or Refractory NHL. American Society for Therapeutic Radiation and Oncology Meeting, Denver, CO. Poster, Presented, 2005.
  • Maris MB, Sandmaier BM, Storer B, Shizuru J, Maloney D, Agura E, Niederwieser D, Pulsipher M, Maziarz RT , McSweeney P, Wade J, Langston A, Chauncey T, Bruno B, Woolfrey A, Little MT, Blume K, Storb R. Unrelated Donor Peripheral Blood Stem Cell (PBSC) Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates. American Society of Hematology Meeting, San Diego, CA. Poster, Presented, 2004.
  • Sorror M, Maris M, Storer B, Sandmaier B, Stuart M, Hegenbart U, Agura E, Chauncey T, Leis J, Pulsipher M, McSweeney P, Radich J, Wade J, Bruno B, Langston A, Niederwieser D, Blume K, Storb R, Maloney D. Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL). American Society of Hematology Meeting, San Diego, CA. abst#2323. Poster, Presented, 2004.
  • McSweeney P, Abhyankar S, Petersen F, Devetten M, Arcaroli J, Zeng C, Baron A, Hardiman P, McGuirk J, Bearman S, Nieto Y, Foran J, Pulsipher M, Pavletic S. Tacrolimus and Mycophenolate Mofetil for GVHD Prevention after Unrelated Donor Transplants. American Society of Hematology Meeting, San Diego, CA. Poster, Presented, 2003.
  • Kamani NR, Infante AJ, DeSantes K, Gilman A, Goyal R, Pulsipher M, Wall DA. Fludarabine (FLU) Containing Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT) in Severe Combined Immune Deficiency Syndromes (SCIDS): Interim Results of a Multi-Institutional Trial of the Pediatric Blood and Marrow Transplant Consortium (PBMTC). American Society of Hematology Meeting, San Diego, CA. Poster, Presented, 2003.
  • Sorror ML, Maris M, Storer B, Sandmaier BM, Maloney BG, Stuart MJ, Pulsipher M, McSweeney PA, Leis JF, Wade JC, Blume KG, Storb RF. Nonmyeloablative (NM) Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) with HLA-Matched Unrelated Donor (URD) for Patients (Pts) with Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL). American Society of Hematology Meeting, San Diego, CA. abst#1757. Poster, Presented, 2003.
  • Pulsipher MA, Guitierrez-Ramos JC, Friedrich C, Mulligan RC, Nathan DG, Sieff CA. A murine stromal cell line engineered to express human IL-3 enhances retroviral-mediated gene transfer. American Society of Hematology Meeting, Seattle, WA. Poster, Presented, 1995.
  • Pulsipher MA, Womer R. Weight is superior to body surface area for pediatric dose calculation. American Association for Cancer Research Meeting, San Diego, CA. Poster, Presented, 1992.

Languages

  • English, Fluent.
  • Japanese, Fluent.

Publications

  • Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM (date unknown). Blood and marrow transplant clinical trials network state of the Science Symposium 2014. (pp. 202-24). Vol. 21. Accepted, .
  • Pulsipher MA (date unknown). Continued Role for Radiation in the Conditioning Regimen for Children With ALL. Vol. 39, 262-264. Accepted, .
  • Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Pulsipher MA, Parikh S, Martinez C, Kapoor N, O'Reilly R, Boyer M, Pai SY, Goldman F, Burroughs L, Chandra S, Kletzel M, Thakar M, Connelly J, Cuvelier G, Davila Saldana BJ, Shereck E, Knutsen A, Sullivan KE, DeSantes K, Gillio A, Haddad E, Petrovic A, Quigg T, Smith AR, Stenger E, Yin Z, Shearer WT, Fleisher T, Buckley RH, Dvorak CC (date unknown). Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Vol. 130, 2718-2727. Accepted, .
  • Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL (date unknown). Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Vol. 24, 6175-6184. Accepted, .
  • Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM (date unknown). The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Vol. 3, 4034-4042. Accepted, .
  • Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA (date unknown). Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. Vol. 26, 2365-2371. Accepted, .
  • Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC (date unknown). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Vol. 20, 1710-1718. Accepted, .
  • Pulsipher MA (date unknown). Are CAR T cells better than antibody or HCT therapy in B-ALL?. Vol. 2018, 16-24. Accepted, .
  • Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N, Shaw PJ, Chen AR, Schultz KR, Kreyenberg H, Di Maio L, Cazzaniga G, Eckert C, van der Velden VHJ, Sutton R, Lankester A, Peters C, Klingebiel TE, Willasch AM, Grupp SA, Pulsipher MA (date unknown). More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Vol. 3, 3393-3405. Accepted, .
  • Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S (date unknown). Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Vol. 4, 5414-5424. Accepted, .
  • Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR (date unknown). Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Vol. 55, 2121-2131. Accepted, .
  • Wiener L, Hoag JA, Pelletier W, Shah NN, Shaw BE, Pulsipher MA, Bruce J, Bader P, Willasch AM, Dalissier A, Guilcher G, Anthias C, Confer DL, Sees JA, Logan B, Switzer GE (date unknown). Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. Vol. 54, 1780-1788. Accepted, .
  • Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, Small TN, Chaisson J, Dvorak CC, Murnane M, Kapoor N, Abdel-Azim H, Hanson IC, Martinez C, Bleesing JJH, Chandra S, Smith AR, Cavanaugh ME, Jyonouchi S, Sullivan KE, Burroughs L, Skoda-Smith S, Haight AE, Tumlin AG, Quigg TC, Taylor C, Dávila Saldaña BJ, Keller MD, Seroogy CM, Desantes KB, Petrovic A, Leiding JW, Shyr DC, Decaluwe H, Teira P, Gillio AP, Knutsen AP, Moore TB, Kletzel M, Craddock JA, Aquino V, Davis JH, Yu LC, Cuvelier GDE, Bednarski JJ, Goldman FD, Kang EM, Shereck E, Porteus MH, Connelly JA, Fleisher TA, Malech HL, Shearer WT, Szabolcs P, Thakar MS, Vander Lugt MT, Heimall J, Yin Z, Pulsipher MA, Pai SY, Kohn DB, Puck JM, Cowan MJ, O'Reilly RJ, Notarangelo LD (date unknown). SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Vol. 132, 1737-1749. Accepted, .
  • Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M (date unknown). Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Vol. 3, 3123-3131. Accepted, .
  • Pulsipher MA, Lehmann LE, Bertuch AA, Sasa G, Olson T, Nakano T, Gilio A, Burroughs LM, Lipton JM, Huang JN, Dickerson K, Bertaina A, Zhuang C, Malsch M, Fleming M, Weller E, Shimamura A, Williams DA (date unknown). A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium. Vol. 67, e28444. Accepted, .
  • Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium. (date unknown). Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Vol. 39, 653-667. Accepted, .
  • Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA (date unknown). Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Vol. 24, 2040-2046. Accepted, .
  • Duncan CN, Brazauskas R, Huang J, Shaw BE, Majhail NS, Savani BN, Flowers MED, Battiwalla M, Beebe K, Dietz AC, Dvorak CC, Giller R, Jacobsohn DA, Kletzel M, Martin PL, Nemecek ER, Nuechterlein B, Talano JA, Pulsipher MA, Baker KS (date unknown). Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Vol. 53, 1278-1287. Accepted, .
  • Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH (date unknown). The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. Vol. 33, 1156-64. Accepted, .
  • Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA (date unknown). Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Vol. 132, 1438-1451. Accepted, .
  • Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Hashmi S, Parsons S, Wood WA, Steinberg A, Freytes CO, Dandoy CE, Marks DI, Lazarus HM, Abdel-Azim H, Bitan M, Diaz MA, Olsson RF, Gergis U, Seber A, Wirk B, LeMaistre CF, Ustun C, Duncan C, Rizzieri D, Szwajcer D, Fagioli F, Frangoul H, Knight JM, Kamble RT, Mehta P, Schears R, Satwani P, Pulsipher MA, Aplenc R, Saber W (date unknown). The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Vol. 26, 1747-1756. Accepted, .
  • McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL (date unknown). Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Vol. 25, 1890-1897. Accepted, .
  • Wood WA, Brazauskas R, Hu ZH, Abdel-Azim H, Ahmed IA, Aljurf M, Badawy S, Beitinjaneh A, George B, Buchbinder D, Cerny J, Dedeken L, Diaz MA, Freytes CO, Ganguly S, Gergis U, Almaguer DG, Gupta A, Hale G, Hashmi SK, Inamoto Y, Kamble RT, Adekola K, Kindwall-Keller T, Knight J, Kumar L, Kuwatsuka Y, Law J, Lazarus HM, LeMaistre C, Olsson RF, Pulsipher MA, Savani BN, Schultz KR, Saad AA, Seftel M, Seo S, Shea TC, Steinberg A, Sullivan K, Szwajcer D, Wirk B, Yared J, Yong A, Dalal J, Hahn T, Khera N, Bonfim C, Atsuta Y, Saber W (date unknown). Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Vol. 24, 1928-1935. Accepted, .
  • Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC, Ji J, Han J, O'Gorman MRG, Wayne AS, Raca G (date unknown). Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Vol. 65, e27265. Accepted, .
  • Shereck E, Shenoy S, Pulsipher M, Burns L, Bracey A, Chell J, Snyder E, Nemecek E (date unknown). Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Vol. 19, 1399-402. Accepted, .
  • Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM (date unknown). Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Vol. 19, 1340-7. Accepted, .
  • Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE (date unknown). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?. Vol. 37, 2098-2104. Accepted, .
  • Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R (date unknown). Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Vol. 6, e409-e418. Accepted, .
  • Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP (date unknown). Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. Vol. 36, 2306-2314. Accepted, .
  • Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C (date unknown). Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Vol. 24, 1651-1656. Accepted, .
  • van den Brink M, Uhrberg M, Jahn L, DiPersio JF, Pulsipher MA (date unknown). Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. Vol. 53, 949-959. Accepted, .
  • Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA (date unknown). Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Vol. 48, 1056-64. Accepted, .
  • Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaşan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, West LJ, Pan B, Al Hamarneh YN, Halevy A, Schultz KR (date unknown). Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Vol. 134, 304-316. Accepted, .
  • Aziz MD, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen YB, Choe HK, Etra A, Gergoudis S, Hartwell MJ, Hexner EO, Hogan WJ, Kitko CL, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara JLM, Levine JE (date unknown). Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. Vol. 34, 1898-1906. Accepted, .
  • Esiashvili N, Lu X, Ulin K, Laurie F, Kessel S, Kalapurakal JA, Merchant TE, Followill DS, Sathiaseelan V, Schmitter MK, Devidas M, Chen Y, Wall DA, Brown PA, Hunger SP, Grupp SA, Pulsipher MA (date unknown). Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. Vol. 104, 513-521. Accepted, .
  • Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, Anderlini PN, Beitinjaneh AM, Bredeson C, Cerny J, Chhabra S, Daly A, Diaz MA, Farhadfar N, Frangoul HA, Ganguly S, Gastineau DA, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Norkin M, Olsson RF, Papari M, Savani BN, Szer J, Waller EK, Wirk B, Yared JA, Pulsipher MA, Shah NN, Switzer GE, O'Donnell PV, Confer DL, Shaw BE (date unknown). The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Vol. 25, 1325-1330. Accepted, .
  • Shenoy S, Gaziev J, Angelucci E, King A, Bhatia M, Smith A, Bresters D, Haight AE, Duncan CN, de la Fuente J, Dietz AC, Baker KS, Pulsipher MA, Walters MC (date unknown). Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Vol. 24, 1313-1321. Accepted, .
  • McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ (date unknown). Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Vol. 20, 960-8. Accepted, .
  • Savage SA, Pulsipher MA, Romano A, Berlyne D (date unknown). Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012. Vol. 37, 848-51. Accepted, .
  • Pulsipher M, Kupfer GM, Naf D, Suliman A, Lee JS, Jakobs P, Grompe M, Joenje H, Sieff C, Guinan E, Mulligan R, D'Andrea AD (date unknown). Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Vol. 4, 468-79. Accepted, .
  • Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE (date unknown). MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Vol. 131, 2846-2855. Accepted, .
  • Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS (date unknown). Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Vol. 39, 1865-1877. Accepted, .
  • Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, Bleesing JJ, Edwards S, Dvorak CC, Chaudhury S, Prockop SE, Quinones R, Goldman FD, Quigg TC, Chandrakasan S, Smith AR, Parikh S, Dávila Saldaña BJ, Thakar MS, Phelan R, Shenoy S, Forbes LR, Martinez C, Chellapandian D, Shereck E, Miller HK, Kapoor N, Barnum JL, Chong H, Shyr DC, Chen K, Abu-Arja R, Shah AJ, Weinacht KG, Moore TB, Joshi A, DeSantes KB, Gillio AP, Cuvelier GDE, Keller MD, Rozmus J, Torgerson T, Pulsipher MA, Haddad E, Sullivan KE, Logan BR, Kohn DB, Puck JM, Notarangelo LD, Pai SY, Rawlings DJ, Cowan MJ (date unknown). Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Vol. 135, 2094-2105. Accepted, .
  • Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang HW, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN (date unknown). Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Vol. 18, 363-378. Accepted, .
  • Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M (date unknown). Immunogenicity of CAR T cells in cancer therapy. Vol. 18, 379-393. Accepted, .
  • Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, Shaw BE, Stroncek DF (date unknown). Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Vol. 27, 503.e1-503.e8. Accepted, .
  • Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredeson C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugrue M, Warkentin P, Wingard JR (date unknown). Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Vol. 26, 1210-1217. Accepted, .
  • Shenoy S, Walters MC, Ngwube A, Soni S, Jacobsohn D, Chaudhury S, Grimley M, Chan K, Haight A, Kasow KA, Parikh S, Andreansky M, Connelly J, Delgado D, Godder K, Hale G, Nieder M, Pulsipher MA, Trachtenberg F, Neufeld E, Kwiatkowski JL, Thompson AA (date unknown). Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Vol. 24, 1216-1222. Accepted, .
  • Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee. (date unknown). Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Vol. 61, 1126-8. Accepted, .
  • Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee. (date unknown). Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Vol. 19, 893-7. Accepted, .
  • Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N, Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research. (date unknown). Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Vol. 123, 3504-11. Accepted, .
  • Denton CC, Gange WS, Abdel-Azim H, Jodele S, Kapoor N, Oberley MJ, Wong K, Kim J, Vercio A, Moghaddampour P, Chalam KV, Sierpina D, Gardner RA, Pulsipher MA, Jensen MC, Nagiel A (date unknown). Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Vol. 4, 2158-2162. Accepted, .
  • Pulsipher MA (date unknown). Better BMT for Hurler syndrome--on the level?. Vol. 121, 3785-7. Accepted, .
  • Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, June CH (date unknown). Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. Vol. 8, 285-295. Accepted, .
  • Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE (date unknown). Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Vol. 25, 955-964. Accepted, .
  • Ladetto M, Böttcher S, Kröger N, Pulsipher MA, Bader P (date unknown). Methods and role of minimal residual disease after stem cell transplantation. Vol. 54, 681-690. Accepted, .
  • Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM (date unknown). Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. Vol. 31, 1530-8. Accepted, .
  • Schultz KR, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savasan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, Azadpour S, Ostroumov E, Subrt P, Halevy A, Mostafavi S, Cuvelier GDE (date unknown). Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. Vol. 135, 1287-1298. Accepted, .
  • Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA (date unknown). Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. Vol. 27, 352.e1-352.e5. Accepted, .
  • Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE (date unknown). Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Vol. 104, 844-854. Accepted, .
  • Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL (date unknown). Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Vol. 25, 699-711. Accepted, .
  • Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, Acute Leukemia Committee of the CIBMTR. (date unknown). Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Vol. 24, 726-733. Accepted, .
  • Goyal RK, Han K, Wall DA, Pulsipher MA, Bunin N, Grupp SA, Mada SR, Venkataramanan R (date unknown). Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Vol. 19, 569-75. Accepted, .
  • Taylor DS, Dharmar M, Urquhart-Scott E, Ryan R, Pulsipher MA, Gamis A, Schultz K, Marcin JP (date unknown). Relationship between pediatric blood and marrow transplant center volume and day +100 mortality: Pediatric Blood and Marrow Transplant Consortium experience. Vol. 48, 514-22. Accepted, .
  • Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA (date unknown). One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Vol. 93, 2217-24. Accepted, .
  • Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D (date unknown). Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Accepted, .
  • Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA (date unknown). The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Vol. 123, 2017-25. Accepted, .
  • Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM (date unknown). Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Vol. 123, 1615-20. Accepted, .
  • Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML (date unknown). Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Vol. 325, 833-842. Accepted, .
  • Bhatt ST, Bednarski JJ, Berg J, Trinkaus K, Murray L, Hayashi R, Schulz G, Hente M, Grimley M, Chan KW, Kamani N, Jacobsohn D, Nieder M, Hale G, Yu L, Adams R, Dalal J, Pulsipher MA, Haut P, Chaudhury S, Davis J, Jaroscak J, Andreansky M, Willert J, Shenoy S (date unknown). Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Vol. 25, 556-561. Accepted, .
  • Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V (date unknown). The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Vol. 3, 670-680. Accepted, .
  • Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel-Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR (date unknown). Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Vol. 4, 706-716. Accepted, .
  • Chan AY, Leiding JW, Liu X, Logan BR, Burroughs LM, Allenspach EJ, Skoda-Smith S, Uzel G, Notarangelo LD, Slatter M, Gennery AR, Smith AR, Pai SY, Jordan MB, Marsh RA, Cowan MJ, Dvorak CC, Craddock JA, Prockop SE, Chandrakasan S, Kapoor N, Buckley RH, Parikh S, Chellapandian D, Oshrine BR, Bednarski JJ, Cooper MA, Shenoy S, Davila Saldana BJ, Forbes LR, Martinez C, Haddad E, Shyr DC, Chen K, Sullivan KE, Heimall J, Wright N, Bhatia M, Cuvelier GDE, Goldman FD, Meyts I, Miller HK, Seidel MG, Vander Lugt MT, Bacchetta R, Weinacht KG, Andolina JR, Caywood E, Chong H, de la Morena MT, Aquino VM, Shereck E, Walter JE, Dorsey MJ, Seroogy CM, Griffith LM, Kohn DB, Puck JM, Pulsipher MA, Torgerson TR (date unknown). Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Vol. 11, 239. Accepted, .
  • Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Diaz MA, Badawy SM, Broglie L, Brown V, Dvorak CC, Gonzalez-Vicent M, Hashem H, Hayashi RJ, Jacobsohn DA, Kent MW, Li CK, Margossian SP, Martin PL, Mehta P, Myers K, Olsson R, Page K, Pulsipher MA, Shaw PJ, Smith AR, Triplett BM, Verneris MR, Eapen M (date unknown). Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Vol. 25, 301-306. Accepted, .
  • Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R (date unknown). Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Vol. 104, 380-391. Accepted, .
  • Taraseviciute A, Pulsipher MA (date unknown). Advances in hematopoietic cell transplant for the treatment of hematologic malignancies. Vol. 31, 3-13. Accepted, .
  • Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (date unknown). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. Vol. 378, 439-448. Accepted, .
  • Bar M, Flowers MED, Storer BE, Chauncey TR, Pulsipher MA, Thakar MS, Bethge W, Storb R, Maloney DG, Sandmaier BM (date unknown). Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Vol. 24, 308-313. Accepted, .
  • Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov DN, Kim VHD, Ovadia A, Guthery SL, Pulsipher M, Lilic D, Devlin LA, Christie S, Depner M, Fuchs S, van Royen-Kerkhof A, Lindemans C, Petrovic A, Sullivan KE, Bunin N, Kilic SS, Arpaci F, Calle-Martin O, Martinez-Martinez L, Aldave JC, Kobayashi M, Ohkawa T, Imai K, Iguchi A, Roifman CM, Gennery AR, Slatter M, Ochs HD, Morio T, Torgerson TR, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the Primary Immune Deficiency Treatment Consortium. (date unknown). Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. Vol. 141, 704-717.e5. Accepted, .
  • Wong WH, Bhatt S, Trinkaus K, Pusic I, Elliott K, Mahajan N, Wan F, Switzer GE, Confer DL, DiPersio J, Pulsipher MA, Shah NN, Sees J, Bystry A, Blundell JR, Shaw BE, Druley TE (date unknown). Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Vol. 12. Accepted, .
  • Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL (date unknown). Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Vol. 121, 197-206. Accepted, .
  • Dorsey MJ, Wright NAM, Chaimowitz NS, Dávila Saldaña BJ, Miller H, Keller MD, Thakar MS, Shah AJ, Abu-Arja R, Andolina J, Aquino V, Barnum JL, Bednarski JJ, Bhatia M, Bonilla FA, Butte MJ, Bunin NJ, Chandra S, Chaudhury S, Chen K, Chong H, Cuvelier GDE, Dalal J, DeFelice ML, DeSantes KB, Forbes LR, Gillio A, Goldman F, Joshi AY, Kapoor N, Knutsen AP, Kobrynski L, Lieberman JA, Leiding JW, Oshrine B, Patel KP, Prockop S, Quigg TC, Quinones R, Schultz KR, Seroogy C, Shyr D, Siegel S, Smith AR, Torgerson TR, Vander Lugt MT, Yu LC, Cowan MJ, Buckley RH, Dvorak CC, Griffith LM, Haddad E, Kohn DB, Logan B, Notarangelo LD, Pai SY, Puck J, Pulsipher MA, Heimall J (date unknown). Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. Vol. 41, 38-50. Accepted, .
  • Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, Hastings CA, Winick NJ, Carroll WL, Wood BL, Borowitz MJ, Pulsipher MA, Hunger SP (date unknown). Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. Vol. 106, 46-55. Accepted, .
  • Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorror ML (date unknown). Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Vol. 55, 172-181. Accepted, .
  • Stroncek DF, Shaw BE, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA (date unknown). Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Vol. 24, 175-184. Accepted, .
  • Goldsby R, Pulsipher M, Adams R, Coffin C, Albritton K, Wagner L (date unknown). Unexpected pleural effusions in 3 pediatric patients treated with STI-571. (pp. 694-5). Vol. 24. Accepted, .
  • Dupuis LL, Quinones CM, Ritchie J, Carpenter PA, Bauters T, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Militano O, Pulsipher MA, McCune JS (date unknown). Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". (pp. e235-e236). Vol. 26. Accepted, .
  • Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, Shaw BE (date unknown). Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. (pp. e142-e144). Vol. 26. Accepted, .
  • Doan A, Pulsipher MA (date unknown). Hypogammaglobulinemia due to CAR T-cell therapy. Vol. 65. Accepted, .
  • Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, McManus MP, Pulsipher MA, Yandell M, Bohnsack JF, Jorde LB, Notarangelo LD, Walter JE (date unknown). Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. (pp. 880-2.e10). Vol. 133. Accepted, .
  • Shah NN, Schneiderman J, Kuruvilla D, Bhojwani D, Fry TJ, Martin PL, Schultz KR, Silverman LB, Whitlock JA, Wood B, Vainshtein I, Adams A, Confer D, Pulsipher MA, Chaudhury S, Wayne AS (date unknown). Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. (pp. e28574). Vol. 68. Accepted, .
  • Schultz RK, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad VK, Rocha V, Shenoy S, Strahm B, Veys P, Wall D, Bader P, Grupp SA, Pulsipher MA, Peters C (date unknown). Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. (pp. 1279-87). Vol. 19. Accepted, .
  • Grupp SA, Dvorak CC, Nieder ML, Levine JE, Wall DA, Langholz B, Pulsipher MA, COG Stem Cell Transplant Scientific Committee. (date unknown). Children's Oncology Group's 2013 blueprint for research: stem cell transplantation. Vol. 60, 1044-7. Accepted, .